Rockwell, B., Goldfinger, M., Mantzaris, I., Shastri, A., Saunthararajah, Y., Gritsman, K., . . . Verma, A. Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia. Ferrata Storti Foundation.
Chicago Style (17th ed.) CitationRockwell, Bradley, et al. Metronomic Low-dose Regimen of Decitabine and Venetoclax Is Safe and Reduces Monocyte Burden in Chronic Myelomonocytic Leukemia. Ferrata Storti Foundation.
MLA (9th ed.) CitationRockwell, Bradley, et al. Metronomic Low-dose Regimen of Decitabine and Venetoclax Is Safe and Reduces Monocyte Burden in Chronic Myelomonocytic Leukemia. Ferrata Storti Foundation.
Warning: These citations may not always be 100% accurate.